Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Incubator/Accelerator | Alive

About Vesicode

Vesicode develops advanced molecular tools for sensitive and high-resolution analysis of extracellular vesicles in a drop of blood. The tools are suitable for both academic research and clinical studies. The long-term goal is to save lives by mapping diseases and allowing much earlier diagnosis of several cancers and other treatable diseases than current methods offer.

Vesicode Headquarter Location

England,

United Kingdom

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vesicode

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vesicode is included in 1 Expert Collection, including Cancer.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Vesicode Patents

Vesicode has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • DNA
  • Genetics
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/23/2020

4/20/2021

Molecular biology, Biotechnology, Genetics, Molecular biology techniques, DNA

Grant

Application Date

3/23/2020

Grant Date

4/20/2021

Title

Related Topics

Molecular biology, Biotechnology, Genetics, Molecular biology techniques, DNA

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.